UPDATE 1-Tempus to buy cancer test maker Personalis for $1.5 billion

Personalis
Tempus Al

Personalis

PSNL

0.00

Tempus Al

TEM

0.00

Adds share move in paragraph 2, deal details throughout

July 20 (Reuters) - Tempus AI TEM.O said on Monday it would buy Personalis PSNL.O in an all-stock deal valued at about $1.5 billion, adding a cancer test to the AI-enabled precision medicine firm's oncology portfolio.

Personalis shares fell 5% in premarket trading, while Tempus shares fell 4%.

Tempus will gain access to Personalis' NeXT Personal cancer test, designed to find microscopic traces of tumor DNA in a patient's blood to track treatment response and detect early recurrence.

The acquisition expands on an existing partnership between the companies, under which Tempus invested in Personalis in November 2023 to develop the NeXT Personal test.

The deal is expected to close in late 2026 or early 2027.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.